Skip to main content
SpringerLink
Log in

Lung Cancer in Elderly: Patient-Centered Approach for Optimal Delivery of Care

  • Reference work entry
  • First Online:
Geriatric Medicine

  • 360 Accesses

Abstract

Background: Lung cancer represents the second most prevalent cause of cancer, and the most common cause of cancer-related mortality among men and women in the United States. Over half the patients diagnosed with lung cancer are over the age of 70 years, and addressing cancer treatment in older adults presents distinct challenges. Over the past two decades, substantial progress has been made in the field of lung cancer treatment, particularly with the advent of immunotherapy and targeted therapies in the management of NSCLC. These treatment modalities have demonstrated effectiveness and a favorable tolerance profile, even among elderly individuals.

Objectives: The primary aim of this review is to provide a comprehensive summary of key clinical trials concerning the management of lung cancer in the elderly. Furthermore, it underscores the importance of assessing frailty and incorporating Comprehensive Geriatric Assessment (CGA) in the treatment decisions pertaining to older adults with lung cancer.

Summary: Numerous clinical trials have investigated the benefits of these treatments in fit older adults, with some trials specifically focusing on geriatric populations. In all cases, the results have shown favorable treatment outcomes. It is essential to assess for frailty and adopt a CGA tool to accurately assess a patient’s suitability for treatment, allowing for a more thorough evaluation of an elderly individual’s functional status and suitability for treatment. This approach not only predicts the tolerability and efficacy of treatment but also serves as a valuable predictor of potential treatment-related toxicities. With the advent of new therapies, there is a greater opportunity to offer treatment to older adults with lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Howlader N, et al. SEER cancer statistics review, 1975–2018. Bethesda: National Cancer Institute; 2021. p. 1–25.

    Google Scholar 

  2. https://seer.cancer.gov/statfacts/html/lungb.html. Accessed 23 July 2023.

  3. Siegel RL, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.

    Article  PubMed  Google Scholar 

  4. Smith BD, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–65.

    Article  PubMed  Google Scholar 

  5. Balducci L. Management of cancer in the elderly. Oncology (Williston Park). 2006;20(2):135–43; discussion 144, 146, 151–2.

    PubMed  Google Scholar 

  6. Bonanno L, et al. Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: translating scientific evidence into clinical practice. Crit Rev Oncol Hematol. 2021;163:103378.

    Article  PubMed  Google Scholar 

  7. https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf

  8. Ludmir EB, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5(12):1769–73.

    Article  PubMed  Google Scholar 

  9. Pang HH, et al. Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012. J Clin Oncol. 2016;34(33):3992–9.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Mohile SG, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326–47.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Dubin S, Griffin D. Lung cancer in non-smokers. Mo Med. 2020;117(4):375–9.

    PubMed  PubMed Central  Google Scholar 

  12. Moyer VA, U.S. Preventive Services Task Force. Screening for cognitive impairment in older adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2014;160(11):791–7. https://doi.org/10.7326/M14-0496. PMID: 24663815.

  13. Jonas DE, et al. Screening for lung cancer with low-dose computed tomography: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021;325(10):971–87.

    Article  PubMed  Google Scholar 

  14. Erkmen CP, et al. Adherence to annual lung cancer screening with low-dose CT scan in a diverse population. Cancer Causes Control. 2021;32(3):291–8.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kotwal AA, Walter LC. Cancer screening among older adults: a Geriatrician’s perspective on breast, cervical, colon, prostate, and lung cancer screening. Curr Oncol Rep. 2020;22(11):108.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Dai C, et al. Choice of surgical procedure for patients with non-small-cell lung cancer ≤ 1 cm or > 1 to 2 cm among lobectomy, Segmentectomy, and wedge resection: a population-based study. J Clin Oncol. 2016;34(26):3175–82.

    Article  PubMed  Google Scholar 

  17. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60(3):615–22; discussion 622–3.

    Article  CAS  PubMed  Google Scholar 

  18. Mery CM, et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest. 2005;128(1):237–45.

    Article  PubMed  Google Scholar 

  19. Shirvani SM, et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg. 2014;149(12):1244–53.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Albain KS, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kim CS, Jeter MD. Radiation therapy for early stage non-small cell lung cancer. Treasure Island: StatPearls; 2023.

    Google Scholar 

  22. Ball D, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20(4):494–503.

    Article  PubMed  Google Scholar 

  23. Chang JY, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–7.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Brooks ED, et al. Stereotactic ablative radiation therapy is highly safe and effective for elderly patients with early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2017;98(4):900–7.

    Article  PubMed  Google Scholar 

  25. Kreinbrink P, et al. Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (>/=80years old): extremely safe and effective. J Geriatr Oncol. 2017;8(5):351–5.

    Article  PubMed  Google Scholar 

  26. Chi A, Nguyen NP. Rationale for combing stereotactic body radiation therapy with immune checkpoint inhibitors in medically inoperable early-stage non-small cell lung cancer. Cancers (Basel). 2022;14(13):3144.

    Article  CAS  PubMed  Google Scholar 

  27. Chang JY, et al. I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: interim analysis adverse effects. J Clin Oncol. 2020;38(15_Suppl):9035.

    Article  Google Scholar 

  28. Verma V, et al. Outcomes of stereotactic body radiotherapy for T1-T2N0 small cell carcinoma according to addition of chemotherapy and prophylactic cranial irradiation: a multicenter analysis. Clin Lung Cancer. 2017;18(6):675–681.e1.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Verma V, et al. Multi-institutional experience of stereotactic ablative radiation therapy for stage I small cell lung cancer. Int J Radiat Oncol Biol Phys. 2017;97(2):362–71.

    Article  PubMed  Google Scholar 

  30. Shioyama Y, et al. Clinical outcomes of stereotactic body radiotherapy for patients with stage I small-cell lung cancer: analysis of a subset of the Japanese Radiological Society Multi-Institutional SBRT Study Group database. Technol Cancer Res Treat. 2018;17:1533033818783904.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Pignon JP, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552–9.

    Article  PubMed  Google Scholar 

  32. Strauss GM, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26(31):5043–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Butts CA, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010;28(1):29–34.

    Article  CAS  PubMed  Google Scholar 

  34. Wu YL, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–23.

    Article  CAS  PubMed  Google Scholar 

  35. Felip E, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344–57.

    Article  CAS  PubMed  Google Scholar 

  36. O’Brien M, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274–86.

    Article  PubMed  Google Scholar 

  37. Dillman RO, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323(14):940–5.

    Article  CAS  PubMed  Google Scholar 

  38. Sause WT, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87(3):198–205.

    Article  CAS  PubMed  Google Scholar 

  39. Auperin A, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90.

    Article  CAS  PubMed  Google Scholar 

  40. Dawe DE, et al. Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2016;99:180–5.

    Article  PubMed  Google Scholar 

  41. Santana-Davila R, et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. J Clin Oncol. 2015;33(6):567–74.

    Article  CAS  PubMed  Google Scholar 

  42. Steuer CE, et al. Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small-cell lung cancer: a systematic review. JAMA Oncol. 2017;3(8):1120–9.

    Article  PubMed  Google Scholar 

  43. Antonia SJ, et al. Durvalumab after Chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29.

    Article  CAS  PubMed  Google Scholar 

  44. Faivre-Finn C, et al. Four-year survival with Durvalumab after Chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial. J Thorac Oncol. 2021;16(5):860–7.

    Article  CAS  PubMed  Google Scholar 

  45. Quoix E, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378(9796):1079–88.

    Article  CAS  PubMed  Google Scholar 

  46. Ettinger DS, et al. Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(5):497–530.

    Article  Google Scholar 

  47. NCCN Guidelines. 2023, https://www.nccn.org/

  48. Lindeman NI, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321–46.

    Article  CAS  PubMed  Google Scholar 

  49. Aggarwal C, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(2):173–80.

    Article  PubMed  Google Scholar 

  50. Losanno T, Gridelli C. First-line treatment of metastatic non-small cell lung cancer in the elderly. Curr Oncol Rep. 2021;23(10):119.

    Article  PubMed  Google Scholar 

  51. Maemondo M, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012;7(9):1417–22.

    Article  CAS  PubMed  Google Scholar 

  52. Soria J-C, et al. Osimertinib in untreated<i>EGFR</i>−mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113–25.

    Article  CAS  PubMed  Google Scholar 

  53. Sequist LV, et al. Phase III study of Afatinib or cisplatin plus Pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34.

    Article  CAS  PubMed  Google Scholar 

  54. Camidge DR, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of Alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14(7):1233–43.

    Article  CAS  PubMed  Google Scholar 

  55. Camidge DR, et al. Brigatinib versus Crizotinib in ALK inhibitor–naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16(12):2091–108.

    Article  CAS  PubMed  Google Scholar 

  56. Shaw AT, et al. First-line Lorlatinib or Crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–29.

    Article  CAS  PubMed  Google Scholar 

  57. Shaw AT, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Planchard D, et al. Phase 2 study of Dabrafenib plus Trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. J Thorac Oncol. 2022;17(1):103–15.

    Article  CAS  PubMed  Google Scholar 

  59. Drilon A, et al. Efficacy of selpercatinib in <i>RET</i> fusion–positive non–small-cell lung cancer. N Engl J Med. 2020;383(9):813–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Gainor JF, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22(7):959–69.

    Article  CAS  PubMed  Google Scholar 

  61. Wolf J, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944–57.

    Article  CAS  PubMed  Google Scholar 

  62. Paik PK, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Li BT, et al. Trastuzumab Deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386(3):241–51.

    Article  CAS  PubMed  Google Scholar 

  64. Park K, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Zhou C, et al. Treatment outcomes and safety of Mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7(12):e214761.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Skoulidis F, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.

    Article  CAS  PubMed  Google Scholar 

  68. Herbst RS, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328–39.

    Article  CAS  PubMed  Google Scholar 

  69. Sezer A, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592–604.

    Article  CAS  PubMed  Google Scholar 

  70. Mok TSK, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30.

    Article  CAS  PubMed  Google Scholar 

  71. Nosaki K, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135:188–95.

    Article  PubMed  Google Scholar 

  72. Hellmann MD, et al. Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31.

    Article  CAS  PubMed  Google Scholar 

  73. Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–126.

    Article  CAS  PubMed  Google Scholar 

  74. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian study. Oncologist. 2001;6(Suppl 1):4–7.

    Article  CAS  PubMed  Google Scholar 

  75. Gandhi L, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92.

    Article  CAS  PubMed  Google Scholar 

  76. Langer CJ, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Socinski MA, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301.

    Article  CAS  PubMed  Google Scholar 

  78. West H, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–37.

    Article  CAS  PubMed  Google Scholar 

  79. Paz-Ares L, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51.

    Article  CAS  PubMed  Google Scholar 

  80. Socinski MA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055–62.

    Article  CAS  PubMed  Google Scholar 

  81. Paz-Ares L, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198–211.

    Article  CAS  PubMed  Google Scholar 

  82. Cascone T, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Lee J, et al. PS01.05 surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC: LCMC3 trial primary analysis. J Thorac Oncol. 2021;16(3, Suppl):S59–61.

    Article  Google Scholar 

  84. Forde PM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Wakelee H, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389:491–503.

    Article  CAS  PubMed  Google Scholar 

  86. Lv C, et al. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial. Lung Cancer. 2023;178:151–6.

    Article  CAS  PubMed  Google Scholar 

  87. Tsuboi M, et al. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol. 2021;17(31):4045–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Scott SC, et al. EP02.04-007 phase 2 trial of neoadjuvant KRASG12C directed therapy with Adagrasib (MRTX849) with or without Nivolumab in resectable NSCLC (neo-KAN). J Thorac Oncol. 2022;17(9, Suppl):S235.

    Article  Google Scholar 

  89. Goto K, et al. LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): interim results from the phase 2 DESTINY-Lung02 trial. Ann Oncol. 2022;33:S1422.

    Article  Google Scholar 

  90. Li BT, et al. Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). J Clin Oncol. 2022;40(16_suppl):TPS9137-TPS9137.

    Google Scholar 

  91. Halmos B. Abstract CT066: HERTHENA-Lung02: a randomized phase 3 study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR tyrosine kinase inhibitor. Cancer Res. 2023;83(8_Suppl):20230414.

    Google Scholar 

  92. Cancer Tomorrow, World Health Organization. Estimated number of incident cases from 2020 to 2030. 2023, https://gco.iarc.fr/tomorrow/en/dataviz/bubbles?sexes=0&age_start=0&years=2030

  93. Marosi C, Köller M. Challenge of cancer in the elderly. ESMO Open. 2016;1(3):e000020.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Komici K, et al. Frailty in patients with lung cancer: a systematic review and meta-analysis. Chest. 2022;162(2):485–97.

    Article  PubMed  Google Scholar 

  95. Goede V. Frailty and cancer: current perspectives on assessment and monitoring. Clin Interv Aging. 2023;18:505–21.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Garcia MV, et al. Screening tools for identifying older adults with cancer who may benefit from a geriatric assessment: a systematic review. JAMA Oncol. 2021;7(4):616–27.

    Article  PubMed  Google Scholar 

  97. Korc-Grodzicki B, Holmes HM, Shahrokni A. Geriatric assessment for oncologists. Cancer Biol Med. 2015;12(4):261–74.

    PubMed  PubMed Central  Google Scholar 

  98. Repetto L, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20(2):494–502.

    Article  PubMed  Google Scholar 

  99. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824–31.

    Article  PubMed  Google Scholar 

  100. Williams GR, et al. Sarcopenia in the older adult with cancer. J Clin Oncol. 2021;39(19):2068–78.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Hurria A, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Li D, et al. Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial. JAMA Oncol. 2021;7(11):e214158.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Kalsi T, et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer. 2015;112(9):1435–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Battisti NML, et al. Targeted therapies in older adults with solid tumors. J Clin Oncol. 2021;39(19):2128–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Gomes F, et al. A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study. ESMO Open. 2021;6(1):100042.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Corre R, et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol. 2016;34(13):1476–83.

    Article  CAS  PubMed  Google Scholar 

  107. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol. 2011;22(1):30–8.

    Article  CAS  PubMed  Google Scholar 

  108. Aapro M, Johnson J. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours. Gerontology. 2005;51(5):287–96.

    Article  CAS  PubMed  Google Scholar 

  109. Bloom HG, et al. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc. 2009;57(5):761–89.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Brandt NJ, Piechocki JM. Treatment of insomnia in older adults: re-evaluating the benefits and risks of sedative hypnotic agents. J Gerontol Nurs. 2013;39(4):48–54.

    Article  PubMed  Google Scholar 

  111. Minkel J, Krystal AD. Optimizing the pharmacologic treatment of insomnia: current status and future horizons. Sleep Med Clin. 2013;8(3):333–50.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Maloney KW, Kagan SH. Adherence and oral agents with older patients. Semin Oncol Nurs. 2011;27(2):154–60.

    Article  PubMed  Google Scholar 

  113. Muluneh B, et al. Improved adherence rates and clinical outcomes of an integrated, closed-loop, pharmacist-led oral chemotherapy management program. J Oncol Pract. 2018;14(6):e324–34.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SUNY Upstate Medical University, Syracuse, NY, USA

    Ghanshyam H. Ghelani & Alina Basnet

  2. Hematology-Oncology Associates of CNY, Syracuse, NY, USA

    Ajeet Gajra

  3. Exigent Research Network, Tacoma, WA, USA

    Ajeet Gajra

Authors
  1. Ghanshyam H. Ghelani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alina Basnet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ajeet Gajra
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. California Association of Long Term Care Medicine, Newbury Park, CA, USA

    Michael R. Wasserman

  2. Betty Irene Moore School of Nursing, University of California, Davis, Sacramento, CA, USA

    Debra Bakerjian

  3. Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA

    Sunny Linnebur

  4. Division of Geriatrics, SUNY Upstate Medical University, Syracuse, NY, USA

    Sharon Brangman

  5. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    Matteo Cesari

  6. Section of Geriatric Medicine, Division of Internal Medicine, Department of Medicine, Cedars-Sinai, Beverly Hills, CA, USA

    Sonja Rosen

Section Editor information

  1. Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ, USA

    Armin Shahrokni MD

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Ghelani, G.H., Basnet, A., Gajra, A. (2024). Lung Cancer in Elderly: Patient-Centered Approach for Optimal Delivery of Care. In: Wasserman, M.R., Bakerjian, D., Linnebur, S., Brangman, S., Cesari, M., Rosen, S. (eds) Geriatric Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-74720-6_79

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-74720-6_79

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-74719-0

  • Online ISBN: 978-3-030-74720-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation